Tumor mutational burden standardization initiatives: Recommendations for consistent tumor mutational burden assessment in clinical samples to guide immunotherapy treatment decisions-Reference-Cited by-同舟云学术

Tumor mutational burden standardization initiatives: Recommendations for consistent tumor mutational burden assessment in clinical samples to guide immunotherapy treatment decisions

Published:2019-03-07 Issue:8 Volume:58 Page:578-588
ISSN:1045-2257
Container-title:Genes, Chromosomes and Cancer
language:en
Short-container-title:Genes Chromosomes Cancer

Author:

Stenzinger Albrecht¹^ORCID,Allen Jeffrey D.²,Maas Jörg³,Stewart Mark D.²,Merino Diana M.²,Wempe Madison M.²,Dietel Manfred⁴

Affiliation:

1. Institute of Pathology, University Hospital Heidelberg (on behalf of QuIP® GmbH, Berlin, Germany) Heidelberg Germany

2. Science Policy, Friends of Cancer Research Washington District of Columbia

3. Management DepartmentQuIP® GmbH Berlin Germany

4. Institute of Pathology, Charité Berlin (on behalf of QuIP® GmbH, Berlin, Germany) Berlin Germany

Funder

F. Hoffmann-La Roche AG

Merck Sharp and Dohme

Memorial Sloan-Kettering Cancer Center

Johns Hopkins University

Columbia University

Thermo Fisher Scientific

Regeneron Pharmaceuticals, Inc.

Pfizer

Merck

Illumina

Genentech

AstraZeneca

Publisher

Wiley

Subject

Cancer Research,Genetics

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/gcc.22733

Reference78 articles.

1. Neoantigens in cancer immunotherapy

2. Signatures of mutational processes in human cancer

3. Mutational heterogeneity in cancer and the search for new cancer-associated genes

4. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden

5. Genomic Analysis of Tumor Microenvironment Immune Types across 14 Solid Cancer Types: Immunotherapeutic Implications

Cited by 160 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Harmonization of tumor mutation burden testing with comprehensive genomic profiling assays: an IQN Path initiative;Journal for ImmunoTherapy of Cancer;2024-02

2. Enhancing the quality of panel-based tumor mutation burden assessment: a comprehensive study of real-world and in-silico outcomes;npj Precision Oncology;2024-01-23

3. Recent advances in personalized cancer immunotherapy with immune checkpoint inhibitors, T cells and vaccines;Personalized Medicine;2024-01

4. Impact of tissue-agnostic approvals on management of primary brain tumors;Trends in Cancer;2024-01

5. Evaluation of potential biomarkers for lenvatinib plus pembrolizumab among patients with advanced endometrial cancer: results from Study 111/KEYNOTE-146;Journal for ImmunoTherapy of Cancer;2024-01